Systemic treatment with the pluripotent cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) was also explored as an immunomodulating therapy for the prevention of bacterial infections in experimental stroke. This evidence concerns the gene CSF2 and stroke disorder.